Results 61 to 70 of about 49,882 (187)
Third‐Generation Nanopore Sequencing for Post‐Transplant Chimerism Monitoring
HLA, Volume 107, Issue 6, June 2026.ABSTRACT Post‐transplant chimerism monitoring is a cornerstone of hematopoietic stem cell transplantation (HSCT) follow‐up, providing early and clinically actionable information on engraftment, graft rejection and disease relapse. Analytical strategies have progressively evolved from STR‐based assays towards more sensitive molecular approaches ...
Pascal Pedini +7 more
wiley +1 more source
Acute myelogenous leukaemia in children
European Journal of Pediatrics, 1989 Acute myelogenous leukaemia in childhood is considerably more resistant to chemotherapy than the acute lymphocytic leukaemias. Recently, more aggressive therapy has improved the outlook for children with this difficult form of leukaemia. Long-term disease-free survival of children achieving remission has been reported to be more than 40% in some ...
openaire +3 more sources
Treatment of acute myelogenous leukaemia [PDF]
Journal of Internal Medicine, 1997 The author presents a brief overview of current therapy in adults of various ages with acute myelogenous leukaemia, including remission induction and post‐remission treatment and the use of haematopoietic growth factors.
openaire +3 more sources
Immunoreactive Calcitonin: A Tumor Marker for Myelogenous Leukemias
The International Journal of Biological Markers, 1990 In a series of 59 patients with chronic or acute myelogenous leukemia (CML, AML) we investigated whether circulating immunoreactive human calcitonin (i-hCT) levels correlate with diagnosis, response to therapy and clinical course. I-hCT was detectable in
P. Foa +6 more
doaj +1 more source
A patient with maculopapular rash and lichenoid skin damage caused by ponatinib
Journal of International Medical Research, 2020 Tyrosine kinase inhibitors (TKIs) are invaluable for the treatment of patients with chronic myelogenous leukemia. Although TKIs are generally better tolerated than traditional chemotherapy, dermatologic side effects are common and present a significant ...
Ingrid Anna Teigen +2 more
doaj +1 more source
BMC Complementary and Alternative Medicine, 2012 Background In this report, the isorhamnetin 3-o-robinobioside and its original extract, the ethyl acetate extract, from Nitraria retusa leaves, were evaluated for their ability to induce antioxidant and antigenotoxic effects in human chronic myelogenous ...
Boubaker Jihed +4 more
doaj +1 more source
Iranian Journal of Allergy, Asthma and Immunology, 2006 Previous studies have demonstrated some significant differences in HLA allele frequencies in leukemic patients and normal subjects. We have analyzed HLA class II alleles and haplotypes in 60 Iranian patients with acute myelogenous leukemia (AML) and 180
Abdolfattah Sarafnejad +7 more
doaj
HLA Class II Allele and Haplotype Frequencies in Iranian Patients with Leukemia
Iranian Journal of Allergy, Asthma and Immunology, 2007 Previous studies demonstrated significant differences in a number of HLA allele frequencies in leukemia patients and normal subjects. In this study, we have analyzed HLA class II alleles and haplotypes in 110 leukemia patients (60 acute myelogenous ...
Farideh Khosravi +7 more
doaj
The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia
Oncology Reviews, 2011 Imatinib mesylate, a small-molecule inhibitor of BCRABL tyrosine kinase activity, has emerged as the well-recognized standard of treatment for chronic myelogenous leukemia (CML). Indeed, both its efficacy, tolerability, as well as cost-effectiveness have
Camillo Porta, Federica Tagliani
doaj +1 more source
Chronic myelogenous leukemia on target
Cancer Medicine, 2018 Chronic myelogenous leukemia (CML) is commonly treated with tyrosine kinase inhibitors (TKIs) that inhibit the pro‐leukemic activity of the BCR‐ABL1 oncoprotein.
Veronika Némethová, Filip Rázga
doaj +1 more source